The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
24 week, single center, prospective, randomized, double-blind treatment study of valsartan
(80 mg/bid, increased to 160 mg/bid) or placebo in addition to other general medical therapy
in patients with persistent atrial fibrillation (AF) undergoing electrical cardioversion to
restore normal sinus rhythm (SR).